B Braun OEM Division - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

B Braun OEM Division


B. Braun OEM Division

Customized Kits – from concept to customization.

As one of the leading companies in the healthcare market, B. Braun is your professional and reliable outsourcing partner for pharmaceutical contract manufacturing and customized medical devices. Our product line has everything for safe and exact infusion therapy.

Based on our extensive product portfolio, long lasting experiences and our complete project management capabilities we are your ideal partner to provide you with standard products or products with modified characteristics assembled in customized kits. Based on your drug we can offer you all disposable items which are required for a certain procedure. You can use your possibility to combine different products or to pair one of our products with one of yours. Your possibilities are nearly endless. We also cover registration issues on the basis of your indications (e.g. labeling, instructions for use, documents, registration).

Visit our booth no. 42F29 at the ICSE in Frankfurt and learn more about how we design, combine and produce customized kits for dozens of applications. We accompany you from your first idea to your individual kit.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here